Literature DB >> 19761868

Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids.

J Allen Crow1, Katye L Herring, Shuqi Xie, Abdolsamad Borazjani, Philip M Potter, Matthew K Ross.   

Abstract

Two major isoforms of human carboxylesterases (CEs) are found in metabolically active tissues, CES1 and CES2. These hydrolytic enzymes are involved in xenobiotic and endobiotic metabolism. CES1 is abundantly expressed in human liver and monocytes/macrophages, including the THP1 cell line; CES2 is expressed in liver but not in monocytes/macrophages. The cholesteryl ester hydrolysis activity in human macrophages has been attributed to CES1. Here, we report the direct inhibitory effects of several endogenous oxysterols and fatty acids on the CE activity of THP1 monocytes/macrophages and recombinant human CES1 and CES2. Using THP1 whole-cell lysates we found: (1) 27-hydroxycholesterol (27-HC) is a potent inhibitor of carboxylesterase activity (IC50=33 nM); (2) 24(S),25-epoxycholesterol had moderate inhibitory activity (IC(50)=8.1 microM); and (3) cholesterol, 7-ketocholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 25-hydroxycholesterol each had little inhibitory activity. 27-HC was a partially noncompetitive inhibitor of recombinant CES1 (K(iapp)=10 nM) and impaired intracellular CES1 activity following treatment of intact THP1 cells. In contrast, recombinant CES2 activity was not inhibited by 27-HC, suggesting isoform-selective inhibition by 27-HC. Furthermore, unsaturated fatty acids were better inhibitors of CES1 activity than saturated fatty acids, while CES2 activity was unaffected by any fatty acid. Arachidonic acid (AA) was the most potent fatty acid inhibitor of recombinant CES1 and acted by a noncompetitive mechanism (K(iapp)=1.7 microM); when not complexed to albumin, exogenous AA penetrated intact THP1 cells and inhibited CES1. Inhibition results are discussed in light of recent structural models for CES1 that describe ligand binding sites separate from the active site. In addition, oxysterol-mediated inhibition of CES1 activity was demonstrated by pretreatment of human liver homogenates or intact THP1 cells with exogenous 27-HC, which resulted in significantly reduced hydrolysis of the pyrethroid insecticide bioresmethrin, a CES1-specific xenobiotic substrate. Collectively, these findings suggest that CE activity of recombinant CES1, cell lysates, and intact cells can be impaired by naturally occurring lipids, which may compromise the ability of CES1 to both detoxify environmental pollutants and metabolize endogenous compounds in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761868      PMCID: PMC2787731          DOI: 10.1016/j.bbalip.2009.09.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  49 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

2.  An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.

Authors:  B A Janowski; P J Willy; T R Devi; J R Falck; D J Mangelsdorf
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

3.  Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1.

Authors:  Sompop Bencharit; Carol C Edwards; Christopher L Morton; Escher L Howard-Williams; Peter Kuhn; Philip M Potter; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2006-08-15       Impact factor: 5.469

4.  Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols.

Authors:  A Venkateswaran; J J Repa; J M Lobaccaro; A Bronson; D J Mangelsdorf; P A Edwards
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

5.  Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux.

Authors:  Jenny Wong; Carmel M Quinn; Andrew J Brown
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-28       Impact factor: 8.311

Review 6.  Control of gene expression by fatty acids.

Authors:  Jean-Paul Pégorier; Cédric Le May; Jean Girard
Journal:  J Nutr       Date:  2004-09       Impact factor: 4.798

Review 7.  Pest toxicology: the primary mechanisms of pesticide action.

Authors:  John E Casida
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

8.  Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages.

Authors:  Hiroaki Okazaki; Masaki Igarashi; Makiko Nishi; Motohiro Sekiya; Makiko Tajima; Satoru Takase; Mikio Takanashi; Keisuke Ohta; Yoshiaki Tamura; Sachiko Okazaki; Naoya Yahagi; Ken Ohashi; Michiyo Amemiya-Kudo; Yoshimi Nakagawa; Ryozo Nagai; Takashi Kadowaki; Jun-ichi Osuga; Shun Ishibashi
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

9.  Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice.

Authors:  Bin Zhao; Jingmei Song; Woon N Chow; Richard W St Clair; Lawrence L Rudel; Shobha Ghosh
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.

Authors:  Andrew Rowland; David J Elliot; Kathleen M Knights; Peter I Mackenzie; John O Miners
Journal:  Drug Metab Dispos       Date:  2008-02-06       Impact factor: 3.922

View more
  14 in total

Review 1.  Role of the steroidogenic acute regulatory protein in health and disease.

Authors:  Pulak R Manna; Cloyce L Stetson; Andrzej T Slominski; Kevin Pruitt
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

Review 2.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.

Authors:  Lucy Her; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-12-23       Impact factor: 3.922

Review 3.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

Review 4.  Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review.

Authors:  Yanjiao Xu; Chengliang Zhang; Wenxi He; Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

5.  Silencing carboxylesterase 1 in human THP-1 macrophages perturbs genes regulated by PPARγ/RXR and RAR/RXR: down-regulation of CYP27A1-LXRα signaling.

Authors:  Lee C Mangum; Xiang Hou; Abdolsamad Borazjani; Jung Hwa Lee; Matthew K Ross; J Allen Crow
Journal:  Biochem J       Date:  2018-02-09       Impact factor: 3.857

6.  Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon.

Authors:  J Allen Crow; Victoria Bittles; Katye L Herring; Abdolsamad Borazjani; Philip M Potter; Matthew K Ross
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-04       Impact factor: 4.219

7.  Catabolism of 4-hydroxy-2-trans-nonenal by THP1 monocytes/macrophages and inactivation of carboxylesterases by this lipid electrophile.

Authors:  Abdolsamad Borazjani; Mariola J Edelmann; Katelyn L Hardin; Katye L Herring; J Allen Crow; Matthew K Ross
Journal:  Chem Biol Interact       Date:  2011-08-22       Impact factor: 5.192

8.  Examination of the carboxylesterase phenotype in human liver.

Authors:  Matthew K Ross; Abdolsamad Borazjani; Ran Wang; J Allen Crow; Shuqi Xie
Journal:  Arch Biochem Biophys       Date:  2012-04-16       Impact factor: 4.013

9.  Carboxylesterases: Dual roles in lipid and pesticide metabolism.

Authors:  Matthew K Ross; Timothy M Streit; Katye L Herring
Journal:  J Pestic Sci       Date:  2010       Impact factor: 1.519

10.  A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.

Authors:  Bart J Crielaard; Steffen van der Wal; Twan Lammers; Huong Thu Le; Wim E Hennink; Raymond M Schiffelers; Gert Storm; Marcel Ham Fens
Journal:  Int J Nanomedicine       Date:  2011-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.